Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MB-6 + FOLFOX4
- Development stage
- Unknown
- Lead developer
- Microbio
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
MB-6 + FOLFOX4 is a combination therapeutic regimen investigated for the treatment of metastatic colorectal cancer (mCRC). It consists of MB-6, a multi-component botanical preparation, administered alongside the standard FOLFOX4 chemotherapy regimen, which includes oxaliplatin, 5-fluorouracil, and leucovorin. MB-6 is composed of fermented soybean extract, green tea extract, *Antrodia camphorata* mycelia, spirulina, grape seed extract, and curcumin extract. The combination is designed to enhance the anti-tumor efficacy of chemotherapy while potentially reducing adverse effects such as chemotherapy-induced neutropenia. It has been evaluated in Phase 2 clinical trials to assess its impact on disease progression and patient survival in mCRC patients receiving standard-of-care oxaliplatin-based regimens.
- Other names
- MB-6 plus FOLFOX4MB6 plus FOLFOX4MB 6 plus FOLFOX4
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on MB-6 + FOLFOX4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MB-6 + FOLFOX4.